Originally published as JCO Early Release 10.1200/JCO.2005.02.7888 on April 24 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pierce, L. J. Articles by Weber, B. L. Search for Related Content PubMed PubMed Citation Articles by Pierce, L. J. Articles by Weber, B. L. Social Bookmarking                            What's this?

Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer

Lori J. Pierce, Albert M. Levin, Timothy R. Rebbeck, Merav A. Ben-David, Eitan Friedman, Lawrence J. Solin, Eleanor E. Harris, David K. Gaffney, Bruce G. Haffty, Laura A. Dawson, Steven A. Narod, Ivo A. Olivotto, Andrea Eisen, Timothy J. Whelan, Olufunmilayo I. Olopade, Claudine Isaacs, Sofia D. Merajver, Julia S. Wong, Judy E. Garber, Barbara L. Weber

From the University of Michigan School of Medicine; University of Michigan School of Public Health, Ann Arbor, MI; Center for Clinical Epidemiology and Biostatistics and Abramson Family Cancer Research Institute, University of Pennsylvania; University of Pennsylvania School of Medicine, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT; UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ; Lombardi Cancer Center, Georgetown University, Washington, DC; Dana-Farber Cancer Institute, Harvard University, Boston, MA; University of Chicago School of Medicine, Chicago, IL; Princess Margaret Hospital, University of Toronto, Toronto; Hamilton Regional Cancer Center, Hamilton, Ontario; British Columbia Cancer Agency, Victoria, BC, Canada; and Sheba Medical Center, Ramat Gan, Israel

Address reprint requests to and reprint requests to Lori J. Pierce, MD, Department of Radiation Oncology, University of Michigan School of Medicine, 4308 Cancer and Geriatrics Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0010; e-mail: ljpierce{at}umich.edu

PURPOSE: We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation carriers with breast cancer versus that of matched sporadic controls.

METHODS: A total of 160 BRCA1/2 mutation carriers with breast cancer were matched with 445 controls with sporadic breast cancer. Primary end points were rates of in-breast tumor recurrence (IBTR) and contralateral breast cancers (CBCs). Median follow-up was 7.9 years for mutation carriers and 6.7 years for controls.

RESULTS: There was no significant difference in IBTR overall between carriers and controls; 10- and 15-year estimates were 12% and 24% for carriers and 9% and 17% for controls, respectively (hazard ratio [HR], 1.37; P = .19). Multivariate analyses for IBTR found BRCA1/2 mutation status to be an independent predictor of IBTR when carriers who had undergone oophorectomy were removed from analysis (HR, 1.99; P = .04); the incidence of IBTR in carriers who had undergone oophorectomy was not significantly different from that in sporadic controls (P = .37). CBCs were significantly greater in carriers versus controls, with 10- and 15-year estimates of 26% and 39% for carriers and 3% and 7% for controls, respectively (HR, 10.43; P < .0001). Tamoxifen use significantly reduced risk of CBCs in mutation carriers (HR, 0.31; P = .05).

CONCLUSION: IBTR risk at 10 years is similar in BRCA1/2 carriers treated with breast conservation surgery who undergo oophorectomy versus sporadic controls. As expected, CBCs are significantly increased in carriers. Although the incidence of CBCs was significantly reduced in mutation carriers who received tamoxifen, this rate remained significantly greater than in controls. Additional strategies are needed to reduce contralateral cancers in these high-risk women.

Supported by grants from The Breast Cancer Research Foundation (to L.J.P. and B.L.W.), National Institutes of Health Grant No. M01 RR00064 (to D.K.G.), and National Cancer Institute Grant No. P30 CA51008-12 (to C.I.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. G. Haffty, D. H. Choi, S. Goyal, A. Silber, K. Ranieri, E. Matloff, M. H. Lee, M. Nissenblatt, D. Toppmeyer, and M. S. Moran Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups Ann. Onc., October 1, 2009; 20(10): 1653 - 1659. [Abstract] [Full Text] [PDF]

				A. D. Hamberger, D. H. Roukos, and T. A. Buchholz Radiation therapy for breast cancer. N. Engl. J. Med., March 26, 2009; 360(13): 1362 - 1362. [Full Text] [PDF]

				A. Recht Contralateral Prophylactic Mastectomy: Caveat Emptor J. Clin. Oncol., March 20, 2009; 27(9): 1347 - 1349. [Full Text] [PDF]

				M. J. Hooning, B. M.P. Aleman, M. Hauptmann, M. H.A. Baaijens, J. G.M. Klijn, R. Noyon, M. Stovall, and F. E. van Leeuwen Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer J. Clin. Oncol., December 1, 2008; 26(34): 5561 - 5568. [Abstract] [Full Text] [PDF]

				W. G. Newman, K. D. Hadfield, A. Latif, S. A. Roberts, A. Shenton, C. McHague, F. Lalloo, S. Howell, and D. G. Evans Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients Clin. Cancer Res., September 15, 2008; 14(18): 5913 - 5918. [Abstract] [Full Text] [PDF]

				D. H. Roukos, E. Lykoudis, and T. Liakakos Genomics and Challenges Toward Personalized Breast Cancer Local Control J. Clin. Oncol., September 10, 2008; 26(26): 4360 - 4361. [Full Text] [PDF]

				P. L. Nguyen, A. G. Taghian, and J. R. Harris In Reply J. Clin. Oncol., September 10, 2008; 26(26): 4361 - 4362. [Full Text] [PDF]

				M. D. Palma, S. M. Domchek, J. Stopfer, J. Erlichman, J. D. Siegfried, J. Tigges-Cardwell, B. A. Mason, T. R. Rebbeck, and K. L. Nathanson The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families Cancer Res., September 1, 2008; 68(17): 7006 - 7014. [Abstract] [Full Text] [PDF]

				E. Briasoulis and D. H. Roukos Contralateral Prophylactic Mastectomy: Mind the Genetics J. Clin. Oncol., April 10, 2008; 26(11): 1909 - 1910. [Full Text] [PDF]

				D. J. Brenner, I. Shuryak, S. Russo, and R. K. Sachs In Reply: J. Clin. Oncol., February 20, 2008; 26(6): 1015 - 1016. [Full Text] [PDF]

				L. R. Susswein, C. Skrzynia, L. A. Lange, J. K. Booker, M. L. Graham III, and J. P. Evans Increased Uptake of BRCA1/2 Genetic Testing Among African American Women With a Recent Diagnosis of Breast Cancer J. Clin. Oncol., January 1, 2008; 26(1): 32 - 36. [Abstract] [Full Text] [PDF]

				M. R Kell and J. P Burke Management of breast cancer in women with BRCA gene mutation BMJ, March 3, 2007; 334(7591): 437 - 438. [Full Text] [PDF]

				M. K. Schmidt, R. A.E.M. Tollenaar, S. R. de Kemp, A. Broeks, C. J. Cornelisse, V. T.H.B.M. Smit, J. L. Peterse, F. E. van Leeuwen, and L. J. Van 't Veer Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation J. Clin. Oncol., January 1, 2007; 25(1): 64 - 69. [Abstract] [Full Text] [PDF]